Novartis
$141.00Change from previous close: −0.04%Absolute change: −$0.05
At a glance
- Revenue growth
- +9.57%
- 2025 vs 2024
- Net income growth
- +17.11%
- 2025 vs 2024
- Net margin
- 24.7%
- 2024: 23.1%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 110,949 | 102,246 | 99,945 | 117,453 | 131,795 |
| Current assets | 30,460 | 29,704 | 30,481 | 36,910 | 45,718 |
| Cash and equivalents | 11,435 | 11,459 | 13,393 | 7,517 | 12,407 |
| Short-term investments | 98.0 | 1,892 | 680 | 11,209 | 15,817 |
| Receivables | 10,833 | 9,131 | 9,247 | 9,801 | 9,563 |
| Inventory | 6,269 | 5,723 | 5,913 | 7,175 | 6,666 |
| Net property, plant and equipment | 12,352 | 10,873 | 10,924 | 12,195 | 13,106 |
| Goodwill | 25,567 | 24,756 | 23,341 | 29,301 | 29,595 |
| Other intangible assets | 29,411 | 26,915 | 26,879 | 31,644 | 28,683 |
| Long-term investments | 1,091 | 1,128 | 1,827 | 1,606 | 2,268 |
| Current liabilities | 27,278 | 28,692 | 26,390 | 28,656 | 30,208 |
| Accounts payable | 4,456 | 4,572 | 4,926 | 5,146 | 5,553 |
| Long-term debt | 27,935 | 21,366 | 18,436 | 20,244 | 22,902 |
| Total debt | 35,376 | 31,258 | 26,348 | 27,909 | — |
| Total liabilities | 64,400 | 58,120 | 53,195 | 58,030 | 63,973 |
| Total equity (incl. minority) | 46,549 | 44,126 | 46,750 | 59,423 | 67,822 |
| Retained earnings | 44,720 | 46,561 | 49,649 | 63,540 | 70,989 |
| Minority interest | 419 | 80.0 | 83.0 | 81.0 | 167 |